TABLE 1.

Clinical and Imaging Characteristics of the 4 Patients in the Study Group

Patient Number	Age and Sex	Initial Disease Status	Treatment Administered	CT Findings After Treatment	Outcome
1	47 F	11-cm pelvic sidewall recurrence of colonic adenocarcinoma	16 cycles of FOLFIRI (olinic acid, 5-f luorouracil, irinotecan) and bevacizumab	Marked shrinkage of mass with new intralesional loculated air and fistulous track to colon	Radical resection with takedown of fistula, intraoperative radiation, and adjuvant chemotherapy. Alive with no evidence of disease 5 mos later
2	50 F	Stage IV melanoma with pulmonary, hepatic, splenic, and peritoneal metastases, including 6.1-cm pelvic mass	2 cycles of XL184	Direct visualization of fistula from pelvic mass to small bowel with new associated small bowel obstruction. Simultaneous development of a fistula between a large pulmonary metastasis and the tracheobronchial tree Shrinkage of other metastases. Attempted laparascopic diversion of ileostomy unsuccessful because of disease extent	Treatment converted to palliative care. Died 1 month later
3	60 F	Large gastric gastrointestinal stromal tumor with hepatic and peritoneal metastases, including a 7-cm upper abdominal implant	Progressed on imatinib 400 mg 2 times a day. Changed to sunitinib 37.5 mg qD. 2 cycles of sunitinib 37.5 mg qD.	New air foci in upper abdominal implant extending to the transverse colon. Shrinkage of other metastases	Treatment converted to palliative care. Died 5 mos later
4	61 M	Large locally recurrent renal cell carcinoma in right nephrectomy bed with pulmonary metastases	3 cycles of sunitinib 50 mg daily (4 weeks on, 2 weeks off)	New fistula between tumor and bowel with passage of oral contrast into mass. Stability of other metastases	Died 1 month later

qD indicates four times a day.